KOSDAQBiotech & Pharma476830

Rznomics

₩18,680▲ 1.19%2026-11-18 close
Market Cap
₩526.5B
Turnover
₩2.6B
Volume
140K
Shares out.
28.2M
PER
—
PBR
12.7×
EPS
-₩829
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Rznomics: RNA platform validation vs. cumulative losses

Rznomics is accumulating clinical data and licensing milestones for its RNA correction platform, while its disclosed results show losses in every year from 2022 to 2025 and in each of the last five quarters.

  1. 1

    On the 2025 disclosure, revenue was KRW 7.92 billion, operating loss was KRW 14.6 billion, and net loss attributable to controlling shareholders was KRW 103.8 billion. The net loss widened far more than the operating loss.

  2. 2

    RZ-001 has reported interim results in Phase 1b/2a for liver cancer and Phase 1/2a for glioblastoma. At ASNO 2026 in June 2026, the company said 20 patients completed screening, 10 were treated, and no new treatment-related safety concern had been identified.

  3. 3

    The May 2025 licensing agreement with Eli Lilly for a hereditary hearing loss therapy was reported at up to USD 1.3 billion. In September 2026, reports said talks on indication expansion and new licensing deals were under way with Eli Lilly.

  4. 4

    On September 30, 2026, a joint development effort with a domestic RNA company for pure RNA therapeutics was reported. It aims to extend the platform to RNA dosed without a viral vector.

  5. 5

    PER cannot be calculated because the last four quarters show net losses, and P/B sits in a range with a large premium to net assets. The share price appears to reflect clinical and licensing expectations more than current earnings.

02

Business structure

Rznomics develops RNA-based gene therapies, and its core technology is an RNA trans-splicing platform. The technology is described as removing disease-causing RNA and expressing RNA that carries a therapeutic payload.

Existing commercial RNA technologies such as siRNA and ASO mainly suppress disease gene expression, whereas RNA editing is distinguished by directly replacing it with a therapeutic sequence.

The lead internal program is RZ-001, an anticancer gene therapy that targets telomerase mRNA expressed in more than 80% of cancer types.

RZ-001 has been given in combination with the immuno-oncology drugs atezolizumab and bevacizumab to patients with liver cancer who had no prior systemic therapy, and a Phase 1/2a study in recurrent glioblastoma is also under way.

RZ-003, an Alzheimer's candidate based on APOE4 gene editing, is preclinical and has a material transfer agreement with a global big pharma. RZ-004, for inherited retinitis pigmentosa, is being prepared for clinical development in Australia.

Circular RNA is the platform extension axis, and in March 2026 a joint academic study on delivering circular RNA by intravenous injection alone was announced.

The model has the company handle early candidate research and early clinical stages, while late-stage development and commercialization go to large global pharma partners. The clearest example is the May 2025 agreement with Eli Lilly. The business is best viewed through pipeline stage and partnerships.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩0-₩8.1B—
2025Q4₩800M-₩5.4B−655.8%
2026Q1₩400M-₩8.1B−2199.8%
2026Q2₩800M-₩6.9B−848.2%
2026Q3₩400M-₩6.9B−1540.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩0-₩19.2B-₩31.5B——−156.6%
2023₩100M-₩15.5B-₩13.6B−10808.7%—−127.0%
2024₩0-₩12.9B-₩18.9B——−130.2%
2025₩7.9B-₩14.6B-₩103.8B−184.3%−176.3%6.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On the disclosed figures, revenue was KRW 144 million in 2023 and KRW 7.92 billion in 2025, with no revenue data for 2022 and 2024. Operating loss narrowed from KRW 19.2 billion in 2022 to KRW 15.5 billion in 2023 and KRW 12.9 billion in 2024, then widened to KRW 14.6 billion in 2025.

Net loss attributable to controlling shareholders was KRW 31.5 billion in 2022, KRW 13.6 billion in 2023, KRW 18.9 billion in 2024, and KRW 103.8 billion in 2025, when the loss widened sharply from the prior year.

Net loss including non-controlling interests was also KRW 103.8 billion in 2025, so the total loss and the controlling-shareholder loss matched. The disclosures show losses in each year from 2022 through 2025, four consecutive years.

The operating margin improved from -10,808.7% in 2023 to -184.3% in 2025, but this reflects a larger revenue base rather than a sharp cut in losses.

Operating cash flow was -KRW 14.5 billion in 2022, -KRW 14.4 billion in 2023, -KRW 11.2 billion in 2024, and -KRW 10.9 billion in 2025, so cash outflow stayed above KRW 10 billion a year.

At year-end 2025, total equity was KRW 58.9 billion, all of it attributable to controlling shareholders, with total liabilities of KRW 3.96 billion and a debt ratio of 6.7%.

Debt ratios shown as negative for 2022 through 2024 reflect periods of negative equity, and the year-end 2025 equity level coincided with the KOSDAQ listing in December 2025.

Quarterly revenue had no data for the third quarter of 2025, then KRW 830 million in the fourth quarter, KRW 366 million in the first quarter of 2026, KRW 808 million in the second quarter, and KRW 449 million in the third quarter, so quarter-to-quarter swings are large.

Operating loss went from KRW 8.08 billion in the third quarter of 2025 to KRW 5.44 billion in the fourth quarter, then KRW 8.06 billion in the first quarter of 2026, KRW 6.85 billion in the second quarter, and KRW 6.91 billion in the third quarter. The third quarter of 2026 loss was smaller than a year earlier.

The disclosures show five consecutive quarters of losses from the third quarter of 2025 through the third quarter of 2026, and net losses attributable to controlling shareholders over the last four quarters totaled KRW 25.9 billion.

05

Industry analysis

The RNA therapeutics market has seen siRNA and ASO commercialized first to suppress disease gene expression, and RNA editing is viewed as the next-generation step.

On March 9, 2026, NH Investment & Securities named Rznomics a top small-to-mid cap KOSDAQ biotech pick for the year, citing its competitiveness among the global leaders in next-generation RNA editing.

The same brokerage pointed to the possibility of technology transfer for an RNA-based Alzheimer's therapy and validation of the platform technology as key investment points.

In vivo CAR-T is an area where large global pharma companies are investing heavily, and circular RNA approaches are cited as a basis for expansion into it.

Smallinsight Research, an independent research house, analyzed that first human data for an RNA correction anticancer therapy could support a platform-level revaluation, citing earlier approaches such as CAR-T and CRISPR that received a platform premium after first-in-human proof of concept.

In peer terms, OliX Pharmaceuticals relies on siRNA to suppress target gene expression, so even within RNA therapeutics the mode of action differs between suppression and replacement.

A foreign RNA editing candidate's share price surged after it released first efficacy data, which some see as evidence of high sector expectations.

The competitive yardstick is moving from mode of action to clinical and manufacturing capability, so clinical data and production capacity are likely to be the differentiators.

Regulatory benefits tied to orphan drug designation, including priority review, tax relief, waived approval fees, and up to seven years of market exclusivity, shape the development environment for RZ-001.

06

Outlook

Ahead of BIO USA in June 2026, the company said it was preparing one-on-one meetings with global pharma companies and would discuss both pipeline deals for RZ-001, RZ-003 and RZ-004 and platform deals. At that time, the CEO said meetings with several global pharma companies had been confirmed.

The company is also pursuing package deals that combine pipeline and platform technology, which could enlarge deal sizes. A September 2026 report said talks on indication expansion and new licensing were under way with Eli Lilly.

In August 2026, the company's entry into Eli Lilly's Gateway Labs in the United States was reported, and the company said a U.S. R&D center is scheduled to open. A June 2026 report said RZ-003 is planned for technology transfer at the preclinical stage, with short-term results expected within one to two years.

When it presented interim results, the company said additional patient enrollment and long-term follow-up would clarify the clinical value of RZ-001. The company also cautioned against over-reading the interim liver cancer results.

In in vivo CAR-T based on circular RNA, the company plans to expand collaborations with delivery technology companies. The next scheduled regular filing is the 2026 annual report, which is expected to be the first to include fourth-quarter 2026 results and full-year cash flow in the disclosed figures.

07

Valuation

PER
—
PBR
12.7×
ROE
-88.8%
EPS
-₩829
BPS
₩1,452
Dividend per share
₩0

PER cannot be calculated because the last four quarters show net losses, so earnings-based multiple comparisons do not apply. On an asset basis, P/B sits in a range with a large premium to net assets, which suggests the share price reflects clinical and licensing expectations more than current earnings.

The company pays no dividend, so comparisons with industry averages on dividend yield are limited. The 100% bonus share issue announced in June 2026 increases the number of tradable shares, and media described it as a response to the overhang from lock-up expiry.

Because a larger share count changes per-share comparisons, any comparison of the share price against assets or earnings must be redone each time the disclosures are updated.

The core valuation debate is how quickly human validation of the platform converts into licensing value, and how much of the accumulated losses in the meantime the company can absorb.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

External validation through partnering

The May 2025 Eli Lilly agreement, reported at up to USD 1.3 billion, is cited as external validation of the RNA correction platform. A September 2026 report said talks on indication expansion and new licensing were under way with Lilly. Additional agreements would build a record of platform-level deals.

Early clinical data for RZ-001

RZ-001 holds FDA orphan drug and fast track designations. The June 2026 ASNO 2026 update reported 20 patients screened, 10 treated, and no new safety concern identified. The company said some patients showed tumor recurrence control lasting more than six months.

Pipeline breadth

RZ-003 for Alzheimer's has a material transfer agreement with a global big pharma and is planned for licensing at the preclinical stage. RZ-004 for retinal disease is being prepared for clinical work in Australia.

Circular RNA-based in vivo CAR-T is an area attracting large pharma investment, and expansion potential is cited.

09

Bear factors

Accumulated losses and a wider net loss

The controlling-shareholder net loss widened to KRW 103.8 billion in 2025 and the operating loss was KRW 14.6 billion. The disclosures show losses for four consecutive years from 2022 to 2025 and five consecutive quarters through the third quarter of 2026. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 25.9 billion.

Thin revenue base and cash outflow

Revenue was KRW 7.92 billion in 2025, and quarterly revenue in 2026 moved between KRW 366 million and KRW 808 million. Operating cash flow was -KRW 10.9 billion in 2025, and cash outflow has stayed above KRW 10 billion a year. Revenue has not grown enough to absorb the losses.

Early clinical evidence and rising share count

The RZ-001 results are interim with 10 treated patients, and the company itself cautioned against over-interpreting them. A 100% bonus share issue decided in June 2026 increased the number of tradable shares. Media described it as a response to the overhang from lock-up expiry and a share price decline.

10

Risk factors

Clinical risk

RZ-001 data are interim results centered on a small number of patients in liver cancer and glioblastoma. Response rates and safety could change in later enrollment and long-term follow-up. Platform value depends heavily on the outcome of human validation, so interim results leave wide room for interpretation.

Funding and dilution risk

Operating cash outflow was KRW 10.9 billion in 2025, against year-end 2025 total equity of KRW 58.9 billion. If losses continue and equity shrinks, additional funding may be needed. The 100% bonus share issue decided in June 2026 has already increased the number of shares.

Licensing uncertainty

Apart from the Eli Lilly agreement, few platform or pipeline deals have been finalized. If negotiations stall or terms come in lower, expectations for company value could be reset. Negotiation progress can only be tracked through disclosures and media reports.

11

What to watch next

  1. Late March 2027 (statutory filing deadline)

    Filing of the 2026 annual report. This is the first regular filing to include fourth-quarter 2026 results and full-year cash flow, and it will be compared with the 2025 operating loss of KRW 14.6 billion and operating cash outflow of KRW 10.9 billion.

  2. After December 2026 (timing undetermined)

    Whether indication expansion talks with Eli Lilly or a new licensing deal is disclosed. The deal size and terms would become the first public benchmark for platform value.

  3. By end-2027 (within one to two years per June 2026 reporting)

    Whether the preclinical licensing of the RZ-003 Alzheimer's candidate is completed. Completion would be the first example of the platform's pipeline expansion.

  4. Around April 2027 (estimated from the annual conference calendar)

    Updated RZ-001 data at major conferences such as the next AACR. The focus is how patient numbers and response or survival measures change from the interim results.

12

Overall view

Rznomics is built on an RNA trans-splicing platform and holds clinical pipeline assets including RZ-001, along with licensing experience with Eli Lilly.

The disclosed results show small revenue, a wider loss at the operating and controlling-shareholder levels in 2025, four consecutive years of losses from 2022 to 2025, and five consecutive quarters of losses.

The controlling-shareholder net loss over the last four quarters totaled KRW 25.9 billion, and operating cash outflow has exceeded KRW 10 billion each year. Positive factors include the Eli Lilly agreement, human data for RZ-001, and pipeline breadth across RZ-003 and RZ-004.

Negative factors include interim results covering 10 treated patients, accumulated losses and cash outflow, a larger share count after the bonus issue, and a large premium to net assets on P/B. These factors carry comparable weight, and the current data do not settle which side prevails.

The next checkpoint is the 2026 annual report, and further Eli Lilly agreements and the RZ-003 licensing outcome will show the direction of platform value around that time.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharm.edaily.co.kr
  2. mt.co.kr
  3. thebionews.net
  4. mt.co.kr
  5. markets.hankyung.com
  6. thebionews.net
  7. v.daum.net
  8. m.news.nate.com
  9. thebionews.net
  10. etoday.co.kr
  11. biotimes.co.kr
  12. sisajournal-e.com
  13. biotimes.co.kr
  14. biotimes.co.kr
  15. newsis.com
  16. news.nate.com
  17. news.nate.com
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis